MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Status:
RECRUITING
Trial end date:
2030-05-31
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that MK2 inhibition may improve efficacy of mFOLFIRINOX chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC).
Phase:
PHASE1
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Aclaris Therapeutics, Inc. National Cancer Institute (NCI)